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Abstract
Background: Coagulopathy is a major contributing factor to bleeding related mortality even after
achieving adequate surgical control of the haemorrhage in trauma and surgical patients.
Case presentation: A 65 years old Greek man was admitted in our ICU with critical
haemorrhage following renal biopsy. Despite surgical exploration the patient continued to bleed
resulting in a vicious cycle of transfusion, coagulopathy and re-bleeding. After all standard
management options were exhausted, the patient was given rFVIIa (total dose 4,8 mg). Clinical
improvement was noted without adverse thrombotic complications. One month later the same
patient was operated on for a suspected retroperitoneal infected collection that it was assumed to
be the cause of persistent pyrexia. After abdominal washout, he suffered haemorrhagic shock with
postoperative coagulopathy. Standard transfusion therapy was again unsuccessful. The patient was
given rFVIIa again resulting in an immediate reduction in coagulopathic haemorrhage accompanied
by a significant improvement in laboratory measurements and reduction in blood products
requirements.
Conclusion: Published clinical experiences for the use of rFVIIa in trauma patients are limited to
small series and case reports. However, in trauma patients, administration of rFVIIa appears to be
effective in addition to prompt surgical intervention as an adjunctive haemostatic measure to
control life threatening bleeding in appropriately selected patients.
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Background
Coagulopathy is a major contributing factor to bleeding
related mortality even after achieving adequate surgical
control of the haemorrhage in trauma and surgical
patients, particularly when associated with metabolic aci-
dosis and hypothermia [1,2].
Recombinant activated factor VII(rFVIIa) has been
approved since nearly a decade for the prevention and
treatment of bleeding episodes in haemophilic patients
with inhibitors to coagulation factor VII or factor IX [3].
Recent studies reports the successful management of mas-
sive obstetric haemorrhage with the use of rFVIIa[4].
However, administration of rFVIIa appears to be effective
in addition to prompt surgical intervention as an adjunc-
tive haemostatic measure to control life threatening
bleeding in trauma patients as well as postoperative
haemorrhage. Furthermore, recent case reports [5-7] and
case series II [1,8-12], have also suggested a role of rFVIIa
in the management of life threatening bleeding in patients
with trauma induced coagulopathies who do not respond
to conventional treatments.
We describe the successful use of rFVIIa in the manage-
ment of a patient with no pre-existing coagulopathy who
developed refractory bleeding following renal biopsy, for
persistent proteinuria (2,5 gr/day), despite adequate ther-
apy.
Case presentation
A 65 year old Greek man with unremarkable previous
medical history, was admitted to our ICU because of
haemorrhage after renal biopsy. On admission, examina-
tion revealed a respiratory rate of 30/min, a pulse rate of
138/min and a blood pressure of 79/58 mmHg. He was in
a critical condition with profound hypovolaemic shock,
acute renal failure and coagulopathy. Despite volume
resuscitation and transfusion of 8 units of Red Blood Cells
(RBC) and 4 units of Fresh Frozen Plasma (FFP) the
patient developed a rapidly expanding abdomen. He was
transported immediately to the operating room for
laparotomy.
His preoperative airway examination was unremarkable:
mouth opening, oropharyngeal view, thyromental dis-
tance, and neck movement were all normal. For anaes-
thetic induction, after three minutes of pre-oxygenation
with 100% O2  and initiation of cricoid pressure, the
patient received midazolam 2 mg iv, fentanyl 100 mcg iv,
etomidate 16 mg iv, and succinylcholine 80 mg iv.
Anaesthesia was maintained with sevoflurane (MAC 1–
1.2) in air and oxygen (FiO2  50%), and intermittent
boluses of fentanyl and rocuronium. The standard moni-
toring included ECG, capnometry, invasive measurement
of blood pressure and central venous pressure, pulsoxime-
try, diuresis, esophageal and tympanic temperature. Bis-
pectral analysis of the electroencephalogram was used as
a guide for anaesthetic depth and bispectral index levels
were maintained between 40 and 55. Ligation of the
bleeding left kidney vessels was accomplished.
After completion of the operation mechanical ventilation
was continued in ICU. Four hours later the patient
became haemodynamically unstable with a rapid drop of
his haematocrit, while he required increased doses of flu-
ids and vasopressors. A 4-lumen central venous catheter
and a pulmonary artery catheter were inserted via punc-
ture of the internal jugular vein. In addition, 4 units of
RBC, 13 units of FFP and 6 units of platelets were admin-
istered. His status did not stabilise and he was taken
directly to the operating room where bleeding from
splenic vessels was found. The same philosophy of anaes-
thetic management is being applied to the perioperative
period. Emergency splenectomy was carried out. As his
condition further deteriorated administration of rFVIIa, as
last effort to control his bleeding, was decided. A total
dose of 4,8 mg (60 μg/kg) of rFVIIa along with concurrent
transfusion of 4 units of FFP, 2 units of RBC and 6 units
of platelets were given. Remarkably, all signs of bleeding
appeared to cease (Table 1), the patient's haemodynamic
parameters also stabilised and his tissue perfusion and
metabolic acidosis gradually improved. There were no fur-
ther episodes of recurrent haemorrhage. On the second
postoperative day, his trachea was extubated in the oper-
Table 1: Compering charts of haemodynamic parameters after the use of rFVIIa for the 1st time
Before the use of rFVIIa (4,8 mg) After the use of rFVIIa (4,8 mg)
PT 24,1 14,1
aPTT 54,7 47,7
INR 2,15 1,24
PT: Prothrombin Time
aPTT: Partial Prothrombin Time
INR: International Normalisation RatioCases Journal 2008, 1:361 http://www.casesjournal.com/content/1/1/361
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ating room and thereafter he was discharged home on
postoperative day 6.
One month later the patient was operated on for a sus-
pected retroperitoneal infected collection that it was
assumed to be the cause of persistent pyrexia. After
abdominal washout he suffered another episode of severe
intraabdominal bleeding with postoperative coagulopa-
thy. Despite the transfusion of 30 units of FFP, 18 units of
RBC and 6 units of platelets to control his bleeding, no
substantial benefit was observed. We, thereafter, decided
to administer again 12 mg (150 μg/kg) of rFVIIa within 16
hours, which resulted in cessation of bleeding shortly after
the last dose of rFVIIa with no recurrent episodes of haem-
orrhage, and correction of clotting parameters (Table 2).
Discussion
The mechanism of coagulopathy in trauma is complex
and multi factorial. It includes dilutional coagulopathy,
hypothermia, acidosis, hyperfibrinolysis, anaemia and
extensive consumption of platelets and coagulation fac-
tors [13,14].
Administration of high doses of rFVIIa results in a huge
increase of rFVIIa compared with the physiologic state,
leading to faster and higher thrombin generation [9]. The
recently developed cell base model of coagulation sug-
gests that rFVIIa enhances haemostasis at the site of injury
without systemic hypercoagulable effect [13]. In our
report we used doses 4,8 mg (60 μg/kg) and 12 mg (150
μg/kg) of rFVIIa respectively. Because widely different
doses have been used in the published reports, the opti-
mal dosing regimen for rFVIIa has not yet been estab-
lished.
Our observation regarding the apparent efficacy of rFVIIa
is consistent with a growing body of evidence suggesting a
role of rFVIIa for the management of bleeding in surgical
patients [1,4,6,9-11,15]. Complete correction of the INR,
shortening of the PT and marked improvement of aPTT
was achieved after treatment with rFVIIa in our patient.
However, normalisation of laboratory measurements of
coagulation, in particular the PT, is rather artificial and
does not appear to reflect correction of in vivo coagulation
[15].
Previous clinical experience with rFVIIa supports a good
safety profile. More than 6500 patients have received
rFVIIa and only 17 adverse events have been reported. In
the reviewed, 4% thromboembolic events were noted, of
which 1% occurred in trauma patients[10]. In another
study less that 0,05% of serious thromboembolic events
occurred in 400.000 doses[13]. In our patient there was
no clinical evidence of thromboembolic events.
Its relative high cost would be offset by the costs that
would otherwise occur after additional blood transfu-
sions, surgical interventions, shock and other adverse
events associated with haemorrhage. We should also con-
sider the benefits of reduced immunologic and viral load,
and the decreased implication of organ system failure
related to increased transfusion volume.
Conclusion
Although investigational use of rFVIIa in trauma patients
has shown promising results, the data supporting the use
of rFVIIa within trauma have been limited to case series
and anecdotal reports. However, in appropriately selected
trauma patients rFVIIa may play a role as an adjunctive
haemostatic measure in addition to surgical haemostasis.
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Table 2: Compering charts of clotting parameters after the use of rFVIIa for the 2nd time
Before the use of rFVIIa (12 mg) After the use of rFVIIa (12 mg)
PT 16,4 11,7
aPTT 148,4 40,7
INR 1,44 0,99
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